Top

BMC Oral Health

Published in:

Open Access 01-12-2022 | Research

Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial

Authors: Babak Motamed, Arezoo Alaee, Arash Azizi, Hoda Jahandar, Mohammad Javad Kharazi Fard, Aryan Jafari

Published in: BMC Oral Health | Issue 1/2022

Abstract

Aims & background

Pilocarpine is an accepted treatment for xerostomia, but limited research has been conducted on the oral, topical form. The present study aimed to compare the effects of 1 and 2% pilocarpine mouthwash on xerostomic participants.

Methods

In this double-blind clinical trial study, 48 subjects with xerostomia were randomly divided into three groups to measure the effects of 1 and 2% pilocarpine and placebo mouthwashes on saliva levels. The amount of saliva in the 1st and 14th days was measured at 0, 45, 60, and 75 mins, while participants used their mouthwash three times a day for 14 days. On the 1st and 14th days, they filled out the information forms on xerostomia and the medicine’s side effects before and after the intervention.

Results

On the 1st day, the mean salivary flow at 45, 60, and 75 mins in the 2 and 1% pilocarpine mouthwash were significantly higher than in the placebo mouthwash group (p < 0.05). On the 14th day, the mean salivary flow time at 45 mins in the 2% pilocarpine mouthwash group was significantly higher than in the placebo mouthwash group (p = 0.007). Furthermore, the mean salivary flow at 60 and 75 mins in the 2% (p < 0.001) and 1% pilocarpine mouthwash (p = 0.028) was significantly higher than in the placebo group. Moreover, the salivary flow in the 2% pilocarpine mouthwash group was significantly higher than the 1% pilocarpine mouthwash (p < 0.05) during these two times. No side effects were observed in any of the subjects.

Conclusions

The study showed that 5 ml of 2 and 1% pilocarpine mouthwash for 2 weeks increased salivary flow in xerostomic participants compared to placebo without any side effects.

Sarideechaigul W, Priprem A, Limsitthichaikoon S, et al. Efficacy and safety of two artificial saliva-based polymers containing 0.1% pilocarpine for treatment of xerostomia: a randomized clinical pilot trial. J Clin Exp Dent. 2021;13(10):e994–e1000. https://doi.org/10.4317/jced.58415.CrossRefPubMedPubMedCentral

Soares MSM, Cavalcanti RL, Goncalves LFF, de Assis IO. Oral and systemic factors in xerostomia. RGO - Rev Gaúcha Odontol. 2021:69. https://doi.org/10.1590/1981-863720200003720200071.

Jafari A, Alaee A, Ghods K. The etiologies and considerations of dysgeusia: a review of literature. J Oral Biosci. 2021;63(4):319–26. https://doi.org/10.1016/J.JOB.2021.08.006.CrossRefPubMed

Lexomboon D, Tan EC, Höijer J, et al. The effect of Xerostomic medication on oral health in persons with dementia. J Am Med Dir Assoc. 2018;19(12):1080–1085.e2. https://doi.org/10.1016/j.jamda.2018.05.014.CrossRefPubMed

Baharvand M, Khodadoustan A, Mohammadi M, et al. Xerostomia due to systemic disease: a review of 20 conditions and mechanisms. Ann Med Health Sci Res. 2014;4(4):503. https://doi.org/10.4103/2141-9248.139284.CrossRefPubMedPubMedCentral

Kapourani A, Kontogiannopoulos KN, Manioudaki A-E, et al. A review on xerostomia and its various management strategies: the role of advanced polymeric materials in the treatment approaches. Polymers (Basel). 2022;14(5):850. https://doi.org/10.3390/polym14050850.CrossRefPubMed

Millsop JW, Wang EA, Fazel N. Etiology, evaluation, and management of xerostomia. Clin Dermatol. 2017;35(5):468–76. https://doi.org/10.1016/j.clindermatol.2017.06.010.CrossRefPubMed

Fantozzi PJ, Pampena E, Di Vanna D, et al. Xerostomia, gustatory and olfactory dysfunctions in patients with COVID-19. Am J Otolaryngol. 2020;41(6). https://doi.org/10.1016/J.AMJOTO.2020.102721.

Liu B, Dion MR, Jurasic MM, Gibson G, Jones JA. Xerostomia and salivary hypofunction in vulnerable elders: prevalence and etiology. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(1):52–60. https://doi.org/10.1016/j.oooo.2011.11.014.CrossRefPubMed

10.

Åstrøm AN, Lie SA, Ekback G, Gülcan F, Ordell S. Self-reported dry mouth among ageing people: a longitudinal, cross-national study. Eur J Oral Sci. 2019;127(2):130–8. https://doi.org/10.1111/EOS.12601.CrossRefPubMed

11.

Davies AN, Thompson J. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database Syst Rev. 2015;2015(10):7-9.

12.

Meshkatsadat M, Alaee A, Alirezaei S. Management of Xerostomia in Covid-19 patints: a review article. Res Dent Sci. 2021;18(3):228–40 Accessed 23 Apr 2022. http://jrds.ir/article-1-1208-en.html.CrossRef

13.

Chamani G, Zarei MR, Mehrabani M, et al. Assessment of systemic effects of ginger on salivation in patients with post-radiotherapy xerostomia. J Oral Heal Oral Epidemiol. 2017;6(3):130–7 http://johoe.kmu.ac.ir/article_84892.html.

14.

Yang WF, Liao GQ, Hakim SG, Ouyang DQ, Ringash J, Su YX. Is pilocarpine effective in preventing radiation-induced xerostomia? A systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(3):503–11.CrossRefPubMed

15.

Pronin AN, Wang Q, Slepak VZ. Teaching an old drug new tricks: Agonism, antagonism, and biased signaling of pilocarpine through M3 muscarinic acetylcholine receptor. Mol Pharmacol. 2017;92(5):601–12. https://doi.org/10.1124/MOL.117.109678.CrossRefPubMedPubMedCentral

16.

Little JW, Miller CS, Rhodus NL. Little and Falace’s dental Management of the Medically Compromised Patient.; 2018.

17.

Song J-I, Park J-E, Kim H-K, Kim M-E, Kim K-S. Dose- and time-related effects of pilocarpine mouthwash on salivation. J Oral Med Pain. 2017;42(3):72–80. https://doi.org/10.14476/JOMP.2017.42.3.72.CrossRef

18.

Malallah OS, Garcia CMA, Proctor GB, Forbes B, Royall PG. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth). Int J Pharm. 2018;541(1–2):157–66. https://doi.org/10.1016/J.IJPHARM.2018.02.004.CrossRefPubMed

19.

Aromdee C, Ferguson MM, Ledger R, Wall J. A pilot study of the disposition of pilocarpine in plasma, saliva and urine after a single oral dose. Eur J Pharm Sci. 1999;8(2):81–3. https://doi.org/10.1016/S0928-0987(98)00054-2.CrossRefPubMed

20.

Bernardi R, Perin C, Becker FL, et al. Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res = Rev Bras Pesqui medicas e Biol. 2002;35(1):105–10. https://doi.org/10.1590/s0100-879x2002000100015.CrossRef

21.

Adejoke HT, Louis H, Amusan OO, Apebende G. A review on classes, extraction, purification and pharmaceutical importance of plants alkaloid. J Med Chem Sci. 2019;2(4):130–9. https://doi.org/10.26655/JMCHEMSCI.2019.8.2.CrossRef

22.

Nakamura N, Sasano N, Yamashita H, et al. Oral pilocarpine (5mg t.i.d.) used for xerostomia causes adverse effects in Japanese. Auris Nasus Larynx. 2009;36(3):310–3. https://doi.org/10.1016/j.anl.2008.04.008.CrossRefPubMed

23.

de Pereira RMS, MDR B, Ferreira MP, et al. Topical pilocarpine for xerostomia in patients with head and neck cancer treated with radiotherapy. Oral Dis. 2020;26(6):1209–18. https://doi.org/10.1111/ODI.13343.CrossRef

24.

Watanabe M, Yamada C, Komagata Y, Kikuchi H, Hosono H, Itagaki F. New low-dose liquid pilocarpine formulation for treating dry mouth in Sjögren’s syndrome: clinical efficacy, symptom relief, and improvement in quality of life. J Pharm Heal care Sci. 2018;4(1). https://doi.org/10.1186/S40780-018-0099-X.

25.

Park J-E, Song C-W, Kim K-S, Kim M-E. Comparison of the effects of pilocarpine solution and tablet on salivary flow rate. J Oral Med Pain. 2015;40(1):10–6. https://doi.org/10.14476/JOMP.2015.40.1.10.CrossRef

26.

Villa A, Connell CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag. 2015;11:45. https://doi.org/10.2147/TCRM.S76282.CrossRefPubMed

27.

Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc. 1987;115(4):581–4. https://doi.org/10.1016/S0002-8177(87)54012-0.CrossRefPubMed

28.

Karimi M. Comparison of the efficacy of plaque removal of Listerine smart rinse kids and vi– one junior fluoridated mouthwash in children aged 6 to 10 years. Interv Pediatr Dent Open Access J. 2019;3(1):197–200. https://doi.org/10.32474/ipdoaj.2019.03.000155.CrossRef

29.

Duś-Ilnicka I, Krala E, Cholewińska P, Radwan-Oczko M. The use of saliva as a biosample in the light of covid-19. Diagnostics. 2021;11(10). https://doi.org/10.3390/diagnostics11101769.

30.

Azizi A, Lavaf S, Najafi M. Comparison of the effect of different chewing gums and one mouth wash on the amount and pH of saliva in healthy individuals. J Dent (Shiraz Univ Med Sci). 2007;8(3):42–9 https://www.sid.ir/en/journal/ViewPaper.aspx?id=104583.

31.

Theunissen M, Rideaux-Seferina S, Magdelijns FJ, Janssen DJAA, van den Beuken-van EMHJJ. Local Oral pilocarpine drops for relieving xerostomia (dry mouth) in the elderly: a pilot study. Vol 22: Elsevier Inc.; 2021. p. 185–6. https://doi.org/10.1016/j.jamda.2020.06.036.CrossRef

32.

Zimmerman RP, Mark RJ, Tran LM, Juillard GF. Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Int J Radiat Oncol Biol Phys. 1997;37(3):571–5. https://doi.org/10.1016/s0360-3016(96)00557-3.CrossRefPubMed

33.

Nikles J, Mitchell GK, Hardy J, et al. Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: a feasibility study. Palliat Med. 2015;29(10):967–74. https://doi.org/10.1177/0269216315585473.CrossRefPubMed

34.

Kim JH, Ahn HJ, Choi JH, Jung DW, Kwon JS. Effect of 0.1% pilocarpine mouthwash on xerostomia: double-blind, randomised controlled trial. J Oral Rehabil. 2014;41(3):226–35. https://doi.org/10.1111/JOOR.12127.CrossRefPubMed

35.

Turner MD. Hyposalivation and xerostomia: etiology, complications, and medical management. Dent Clin N Am. 2016;60(2):435–43. https://doi.org/10.1016/j.cden.2015.11.003.CrossRefPubMed

Title: Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial
Authors: Babak Motamed
Arezoo Alaee
Arash Azizi
Hoda Jahandar
Mohammad Javad Kharazi Fard
Aryan Jafari
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: BMC Oral Health / Issue 1/2022
Electronic ISSN: 1472-6831
DOI: https://doi.org/10.1186/s12903-022-02576-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial

Abstract

Aims & background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims & background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Effects of stabilized hypochlorous acid on oral biofilm bacteria

Age-related variations in position and morphology of the temporomandibular joint in individuals with anterior openbite and crossbite: a multi-cross-sectional comparative study

MicroRNA-18a regulates the metastatic properties of oral squamous cell carcinoma cells via HIF-1α expression

The influence of bracket torque on external apical root resorption in bimaxillary protrusion patients: a retrospective study

Preoperative factors analysis on root development after regenerative endodontic procedures: a retrospective study

The effect of combined maxillary pad movable appliance and FR-III functional appliance in the treatment of skeletal Class III malocclusion of deciduous teeth